As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
News|Slideshows|September 14, 2024
Now Trending: Updated Colonoscopy Guidelines, Out-of-Pocket Caps for Cancer Patients
Author(s)Brian Nowosielski
Check out this recap of articles published on our sister sites during the past week.
Advertisement
Explore articles from the past week published on Drug Topics’ sister brands AJMC, Formulary Watch, and Managed Healthcare Executive. From trispecific antibodies to ChatGPT’s ability to outperform trainee doctors, read up on recent health care industry news.
READ MORE:
Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our
Advertisement
Related to this article
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
2
Conflicting Measles Reports Perpetuate as Cases Continue to Rise
3
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
4
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
5